Vanta Bioscience Limited has responded to BSE Limited's inquiry regarding recent movement in its share price, confirming compliance with all regulatory disclosure requirements. The company's response, dated 11.03.2026, addresses BSE's clarification request made on 25.02.2026.

Regulatory Compliance Confirmation

The company has affirmed that it has disclosed all material information to BSE Limited that may impact its operations and performance. These disclosures have been made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with applicable circulars, within the stipulated timeframes.

Management's Position on Price Movement

Vanta Bioscience's management has stated that they are not aware of any specific reasons for significant movement in the company's share price. The management emphasized that any price movement is purely market-driven and that the company's management is not connected with the share price fluctuations.

The company has reiterated its commitment to maintaining adherence to compliance requirements under the Listing Regulations and other applicable laws. This response demonstrates the company's proactive approach to regulatory communication and transparency.

Corporate Communication

The clarification was signed by Dopesh Raja Mulakala, Managing Director (DIN: 01176660), and submitted digitally on 11.03.2026. The company requested BSE to take this information on record, completing the regulatory response process for the price movement inquiry.

Vanta Bioscience Limited has announced a key leadership appointment, naming Ms. Pooja Kothari as the company's new Company Secretary and Compliance Officer. The appointment was formally approved by the Board of Directors during their meeting held on January 30, 2026, and takes effect immediately from the same date.

Board Meeting Details

The Board of Directors convened on Friday, January 30, 2026, to deliberate on the appointment. The meeting commenced at 6:30 P.M. and concluded at 7:00 P.M. The appointment was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointee Profile and Qualifications

Ms. Kothari brings substantial expertise to her new role, having worked extensively with private and unlisted public companies. Her professional experience spans 4 years, during which she has developed comprehensive knowledge in Company Law and Secretarial Compliances.

Appointment Terms and Compliance

The appointment has been structured according to terms and conditions recommended by the Nomination and Remuneration Committee (NRC) and subsequently approved by the Board. Key compliance aspects of the appointment include:

• Ms. Kothari has no associations with any Directors or Key Managerial Personnel of the company
• She has not been debarred from holding office by any regulatory authority
• The appointment complies with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Regulatory Disclosure

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI Listing Regulations by informing BSE Limited about this appointment. The notification was signed by Venkata Sathya Murali Dokka, Chief Financial Officer of Vanta Bioscience Limited, ensuring proper corporate governance protocols were followed.

This appointment strengthens the company's compliance framework and demonstrates its commitment to maintaining robust corporate governance standards. Ms. Kothari's expertise in secretarial compliances will be instrumental in ensuring the company meets all regulatory requirements effectively.